Autolus Therapeutics plc Defined Contribution Plan, Cost
Autolus Therapeutics plc (AUTL) reported Defined Contribution Plan, Cost of $1.50 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:DefinedContributionPlanCostRecognized · last filed 2026-03-27
- Autolus Therapeutics plc defined contribution plan, cost for the quarter ending 2021-03-31 was $100.00K, a 0.00% change year-over-year.
- Autolus Therapeutics plc defined contribution plan, cost for the quarter ending 2020-12-31 was $200.00K, a 100.00% increase year-over-year.
- Autolus Therapeutics plc defined contribution plan, cost for the quarter ending 2020-09-30 was $100.00K, a 0.00% change year-over-year.
- Autolus Therapeutics plc defined contribution plan, cost for the quarter ending 2020-06-30 was $100.00K, a 0.00% change year-over-year.
- Autolus Therapeutics plc defined contribution plan, cost for fiscal 2025 was $1.50M, a 50.00% increase from fiscal 2024.
- Autolus Therapeutics plc defined contribution plan, cost for fiscal 2024 was $1.00M, a 150.00% increase from fiscal 2023.
- Autolus Therapeutics plc defined contribution plan, cost for fiscal 2023 was $400.00K, a 33.33% increase from fiscal 2022.
- Autolus Therapeutics plc defined contribution plan, cost for fiscal 2022 was $300.00K, a 0.00% change from fiscal 2021.
| Period end | Defined Contribution Plan, Cost 3 month | Defined Contribution Plan, Cost 3 month as first filed | Defined Contribution Plan, Cost 6 month | Defined Contribution Plan, Cost 6 month as first filed | Defined Contribution Plan, Cost 9 month | Defined Contribution Plan, Cost 9 month as first filed | Defined Contribution Plan, Cost 12 month |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | $1.50M 10-K · filed 2026-03-27 | ||||||
| 2024-12-31 | $1.00M 10-K · filed 2026-03-27 | ||||||
| 2023-12-31 | $400.00K 10-K · filed 2025-03-20 | ||||||
| 2022-12-31 | $300.00K 10-K · filed 2024-03-21 | ||||||
| 2021-12-31 | $300.00K 10-K · filed 2024-03-21 | ||||||
| 2021-03-31 | $100.00K 6-K · filed 2021-05-06 | $300.00K derived: sum of 2 quarters · filed 2023-03-07 | $400.00K derived: sum of 3 quarters · filed 2023-03-07 | $500.00K derived: sum of 4 quarters · filed 2023-03-07 | |||
| 2020-12-31 | $200.00K derived: 20-F 12 month − 6-K 9 month · filed 2023-03-07 | $300.00K derived: sum of 2 quarters · filed 2023-03-07 | $400.00K derived: sum of 3 quarters · filed 2023-03-07 | $300.00K 20-F · filed 2023-03-07 | |||
| 2020-09-30 | $100.00K 6-K · filed 2020-11-05 | $200.00K derived: sum of 2 quarters · filed 2020-11-05 | $100.00K 6-K · filed 2020-11-05 | $400.00K derived: sum of 4 quarters · filed 2022-03-10 | |||
| 2020-06-30 | $100.00K 6-K · filed 2020-08-06 | $200.00K 6-K · filed 2020-08-06 | $300.00K derived: sum of 3 quarters · filed 2022-03-10 | $400.00K derived: sum of 4 quarters · filed 2022-03-10 | |||
| 2020-03-31 | $100.00K 6-K · filed 2021-05-06 | $84.00K 6-K · filed 2020-05-07 | $200.00K derived: sum of 2 quarters · filed 2022-03-10 | $300.00K derived: sum of 3 quarters · filed 2022-03-10 | $400.00K derived: sum of 4 quarters · filed 2022-03-10 | ||
| 2019-12-31 | $100.00K derived: 20-F 12 month − 6-K 9 month · filed 2022-03-10 | $200.00K derived: sum of 2 quarters · filed 2022-03-10 | $300.00K derived: sum of 3 quarters · filed 2022-03-10 | $200.00K 20-F · filed 2022-03-10 | |||
| 2019-09-30 | $100.00K 6-K · filed 2020-11-05 | $58.00K 6-K · filed 2019-11-07 | $200.00K derived: sum of 2 quarters · filed 2020-11-05 | $100.00K 6-K · filed 2020-11-05 | $136.00K 6-K · filed 2019-11-07 | $243.00K derived: sum of 4 quarters · filed 2021-03-04 | |
| 2019-06-30 | $100.00K 6-K · filed 2020-08-06 | $53.00K 6-K · filed 2019-08-08 | $100.00K 6-K · filed 2020-08-06 | $53.00K 6-K · filed 2019-08-08 | $143.00K derived: sum of 3 quarters · filed 2021-03-04 | $65.00K derived: sum of 4 quarters · filed 2021-03-04 | |
| 2019-03-31 | $25.00K 6-K · filed 2020-05-07 | $43.00K derived: sum of 2 quarters · filed 2021-03-04 | -$35.00K derived: sum of 3 quarters · filed 2021-03-04 | $43.00K derived: sum of 4 quarters · filed 2021-03-04 | |||
| 2018-12-31 | $18.00K 20-F · filed 2021-03-04 | -$60.00K derived: sum of 2 quarters · filed 2021-03-04 | $18.00K derived: sum of 3 quarters · filed 2021-03-04 | ||||
| 2018-09-30 | -$78.00K derived: 20-F 9 month − 6-K 6 month · filed 2021-03-04 | $0.00 derived: sum of 2 quarters · filed 2021-03-04 | $0.00 20-F · filed 2021-03-04 | $0.00 20-F · filed 2020-03-03 | |||
| 2018-06-30 | $78.00K 6-K · filed 2019-08-08 | $78.00K 6-K · filed 2019-08-08 | |||||
| 2017-09-30 | $0.00 20-F · filed 2020-03-03 | ||||||
| 2016-09-30 | $0.00 20-F · filed 2018-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 |